Takeda Oncology
Kristina Kurs currently serves as the Head of Data, Digital and Technology for Europe and Canada at Takeda Oncology, having transitioned to this role in August 2022 after previously holding associate director positions in omnichannel go-to-market strategies. Kristina's extensive experience in digital marketing and communications includes a noteworthy tenure at Abbott as a Multichannel Marketing Communication Manager, where effective disease awareness campaigns were developed. Earlier roles at TWIGA Communication Group and Unilever showcased a strong ability to enhance agency profitability and manage successful digital initiatives within the Tea category. Kristina's educational background includes an Executive MBA from IEDC - Bled School of Management, participation in the Takeda Leadership Development Program, and degrees in management, innovation management, and international economics from reputable institutions.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.